Clik here to view.
FDA perspective reinforces safety profile of Pradaxa
The U.S. Food and Drug Administration (FDA) stated that bleeding rates associated with new use of Pradaxa (dabigatran etexilate) do not appear to be higher than those with new use of warfarin.1,2...
View ArticleClik here to view.
All together now: joining forces to combat AF and stroke
A major meeting in Dublin recently saw nine of the most accomplished physicians in their various fields come together to share expert knowledge on atrial fibrillation, stroke treatment and the efficacy...
View ArticleClik here to view.
Safety status of rivaroxaban remains unchanged — EMA
The European Medicines Agency (EMA) has said that the use of a defective device in a pivotal clinical trial of the oral anticoagulant rivaroxaban (Xarelto) does not change its overall safety status or...
View ArticleClik here to view.
Overview of Pharmacological Properties of Warfarin and Novel Oral...
Download PDF Click on image to enlarge Caroline McDermott
View ArticleBrief Overview of the Outcomes from Pivotal Clinical Trials Comparing the...
Download PDF Dabigatran1 Efficacy and safety was investigated in the RE-LY trial, a randomised, non-inferiority trial, designed to compare two fixed doses of dabigatran (150mg and 110mg), each...
View ArticleAnticoagulant Therapy for Stroke Prevention in Patients with Non-Valvular...
Download PDF Stroke in Ireland – Facts and Figures Each year, approximately 10,000 people are admitted to hospitals in Ireland with acute stroke and around 2,000 die – more deaths than breast cancer,...
View ArticlePraxbind ▼ Approved for the Specific Reversal of the Anticoagulant Effects of...
Download PDF Boehringer Ingelheim Ltd. is pleased to announce that Praxbind (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa (dabigatran etexilate)...
View ArticleClik here to view.
Risk of non-stroke CVD outcomes in AF highlighted
Pic: Getty Images A new study has revealed that atrial fibrillation (AF) is associated with a wide range of serious conditions and the risk for a number of these conditions is greater than that of...
View ArticleAtrial fibrillation cognitive decline and dementia
Internationally renowned cardiologist Prof Mårten Rosenqvist outlined the association between long-standing atrial fibrillation and the risk of developing dementia at the recent Irish Heart Foundation...
View ArticleJohnson & Johnson Campaign tackles rising AF challenge
The cardiac awareness raising campaign is being spearheaded by Arrythmia Alliance and Biosense Webster The post Johnson & Johnson Campaign tackles rising AF challenge appeared first on Irish...
View Article
